Two-drug HIV regimen from GSK bolstered by Phase 3 data

Two-drug HIV regimen from GSK bolstered by Phase 3 data

GlaxoSmithKline on Tuesday made its case for an experimental two-drug regimen of its HIV drugs dolutegravir and lamivudine, presenting detailed data from two Phase 3 trials comparing the doublet to a three-drug cocktail in previously untreated HIV patients.

July 25, 2018 / Pharma News